HCP 03
Breast Cancer Specialist · United Kingdom · Consultant
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Pragmatic prescriber focused on real-world applicability and access; cautious on cross-trial comparison.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
4 improved
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“The result is encouraging, but I would want to know which patients benefit most before changing practice.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“My willingness really depends on how practical the monitoring is in a busy clinic.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“I would use it, but selectively — nodal status alone is not enough, I stratify by risk.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“My instinct after recurrence is to change mechanism of action.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“I read it in the context of everything else available, not in isolation.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“Given the setting, I am comfortable with the profile if we monitor properly.”